(Q46919489)

26 December 2017

title

Complete response after treatment with imatinib in pretreated disseminated testicular seminoma with overexpression of c-KIT. (English)

1 reference

26 December 2017

1 reference

1 reference

Rebecca Pedersini

1

1 reference

26 December 2017

Emanuela Vattemi

series ordinal

2

1 reference

26 December 2017

Guido Mazzoleni

series ordinal

3

1 reference

26 December 2017

Claudio Graiff

series ordinal

4

1 reference

26 December 2017

publication date

1 November 2007

1 reference

26 December 2017

Lancet Oncology Commission

published in

1 reference

26 December 2017

volume

8

1 reference

26 December 2017

issue

11

1 reference

26 December 2017

page(s)

1039-1040

1 reference

26 December 2017

Prevalence of KIT expression in human tumors

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970344-3

7 January 2021

Results of treatment after relapse from high-dose chemotherapy in germ cell tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970344-3

7 January 2021

Expression of KIT and epidermal growth factor receptor in chemotherapy refractory non-seminomatous germ-cell tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970344-3

7 January 2021

Management of malignant gastrointestinal stromal tumours

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970344-3

7 January 2021

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970344-3

7 January 2021

Phase II study of imatinib mesylate in chemotherapy refractory germ cell tumors expressing KIT.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970344-3

7 January 2021

Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970344-3

7 January 2021

Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastoma multiforme

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970344-3

7 January 2021

Imatinib in small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970344-3

7 January 2021

Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970344-3

7 January 2021

Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2807%2970344-3

7 January 2021

10.1016/S1470-2045(07)70344-3

Identifiers

DOI

1 reference

26 December 2017

PubMed ID

17976614

1 reference

26 December 2017